157 related articles for article (PubMed ID: 36394530)
1. Application of the patient-reported outcomes continual reassessment method to a phase I study of radiotherapy in endometrial cancer.
Wages NA; Nelson B; Kharofa J; Meier T
Int J Biostat; 2023 May; 19(1):163-176. PubMed ID: 36394530
[TBL] [Abstract][Full Text] [Related]
2. Isotonic design for phase I cancer clinical trials with late-onset toxicities.
Wages NA; Braun TM; Conaway MR
J Biopharm Stat; 2023 May; 33(3):357-370. PubMed ID: 36606874
[TBL] [Abstract][Full Text] [Related]
3. A web tool for designing and conducting phase I trials using the continual reassessment method.
Wages NA; Petroni GR
BMC Cancer; 2018 Feb; 18(1):133. PubMed ID: 29402249
[TBL] [Abstract][Full Text] [Related]
4. The continual reassessment method and its applications: a Bayesian methodology for phase I cancer clinical trials.
Ishizuka N; Ohashi Y
Stat Med; 2001 Sep 15-30; 20(17-18):2661-81. PubMed ID: 11523075
[TBL] [Abstract][Full Text] [Related]
5. A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
Abbas R; Rossoni C; Jaki T; Paoletti X; Mozgunov P
Clin Trials; 2020 Oct; 17(5):522-534. PubMed ID: 32631095
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of irrational dose assignment definitions using the continual reassessment method.
Wages NA; Bagley E
Clin Trials; 2019 Dec; 16(6):665-672. PubMed ID: 31547691
[TBL] [Abstract][Full Text] [Related]
7. Assessment of various continual reassessment method models for dose-escalation phase 1 oncology clinical trials: using real clinical data and simulation studies.
James GD; Symeonides S; Marshall J; Young J; Clack G
BMC Cancer; 2021 Jan; 21(1):7. PubMed ID: 33402104
[TBL] [Abstract][Full Text] [Related]
8. CRM2DIM: A SAS macro for implementing the dual-agent Bayesian continual reassessment method.
Bayar MA; Ivanova A; Le Teuff G
Comput Methods Programs Biomed; 2019 Jul; 176():211-223. PubMed ID: 31200907
[TBL] [Abstract][Full Text] [Related]
9. Designing and evaluating dose-escalation studies made easy: The MoDEsT web app.
Pallmann P; Wan F; Mander AP; Wheeler GM; Yap C; Clive S; Hampson LV; Jaki T
Clin Trials; 2020 Apr; 17(2):147-156. PubMed ID: 31856600
[TBL] [Abstract][Full Text] [Related]
10. A Bayesian dose-finding design for outcomes evaluated with uncertainty.
Schipper MJ; Yuan Y; Taylor JM; Ten Haken RK; Tsien C; Lawrence TS
Clin Trials; 2021 Jun; 18(3):279-285. PubMed ID: 33884907
[TBL] [Abstract][Full Text] [Related]
11. A nonparametric Bayesian method for dose finding in drug combinations cancer trials.
Razaee ZS; Cook-Wiens G; Tighiouart M
Stat Med; 2022 Mar; 41(6):1059-1080. PubMed ID: 35075652
[TBL] [Abstract][Full Text] [Related]
12. DICE: A Bayesian model for early dose finding in phase I trials with multiple treatment courses.
Ursino M; Biard L; Chevret S
Biom J; 2022 Dec; 64(8):1486-1497. PubMed ID: 34729815
[TBL] [Abstract][Full Text] [Related]
13. A simulation-free approach to assessing the performance of the continual reassessment method.
Braun TM
Stat Med; 2020 Dec; 39(30):4651-4666. PubMed ID: 32939800
[TBL] [Abstract][Full Text] [Related]
14. Adaptive dose finding for phase I clinical trials of drugs used for chemotherapy of cancer.
Potter DM
Stat Med; 2002 Jul; 21(13):1805-23. PubMed ID: 12111891
[TBL] [Abstract][Full Text] [Related]
15. Two-stage subgroup-specific time-to-event (2S-Sub-TITE): An adaptive two-stage time-to-toxicity design for subgroup-specific dose finding in phase I oncology trials.
McGovern A; Chapple AG; Ma C
Pharm Stat; 2022 Nov; 21(6):1138-1148. PubMed ID: 35560864
[TBL] [Abstract][Full Text] [Related]
16. Modeling adverse event counts in phase I clinical trials of a cytotoxic agent.
Muenz DG; Braun TM; Taylor JM
Clin Trials; 2018 Aug; 15(4):386-397. PubMed ID: 29779418
[TBL] [Abstract][Full Text] [Related]
17. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
Gerke O; Siedentop H
Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
[TBL] [Abstract][Full Text] [Related]
18. Extending the Continual Reassessment Method to accommodate step-up dosing in Phase I trials.
Braun TM; Mercier F
Stat Med; 2022 Sep; 41(20):3975-3990. PubMed ID: 35662077
[TBL] [Abstract][Full Text] [Related]
19. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method.
Normolle D; Lawrence T
J Clin Oncol; 2006 Sep; 24(27):4426-33. PubMed ID: 16983110
[TBL] [Abstract][Full Text] [Related]
20. Multi-stage dose expansion cohort (MSDEC) design with Bayesian stopping rule.
Wang S; Tan M
J Biopharm Stat; 2022 Jul; 32(4):600-612. PubMed ID: 35699319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
